About Receptos (NASDAQ:RCPT)
Receptos, Inc. (Receptos) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics in immune disorders. Its product candidates span three disease areas. It is developing its lead asset, ozanimod (formerly RPC1063), as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD), which consists of Ulcerative Colitis (UC) and Crohn's Disease (CD). It is developing its second asset, RPC4046, for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis (EoE), for which it has been granted Orphan drug designation. Its research efforts include a preclinical program developing oral, small molecule, positive allosteric modulators (PAMs) of the glucagon-like peptide-1 receptor (GLP-1R) for the treatment of Type 2 Diabetes.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: Bio Therapeutic Drugs
- Symbol: NASDAQ:RCPT
- CUSIP: N/A
- Web: receptos.com
- Trailing EPS: ($5.89)
- Return on Equity: -44.89%
- Return on Assets: -41.50%
Frequently Asked Questions for Receptos (NASDAQ:RCPT)
What is Receptos' stock symbol?
Receptos trades on the NASDAQ under the ticker symbol "RCPT."
How were Receptos' earnings last quarter?
Receptos Inc (NASDAQ:RCPT) posted its quarterly earnings data on Tuesday, May, 5th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.09) by $0.20. View Receptos' Earnings History.
Who are some of Receptos' key competitors?
Some companies that are related to Receptos include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Medivation (MDVN), Kite Pharma (KITE), Exelixis (EXEL), bluebird bio (BLUE), Juno Therapeutics (JUNO), Neurocrine Biosciences (NBIX), Bioverativ (BIVV), Shire-Nps Pharmaceuticals (NPSP), TESARO (TSRO), Adaptimmune Therapeutics PLC (ADAP), Sarepta Therapeutics (SRPT), BeiGene (BGNE), Auspex Pharmaceuticals (ASPX), AveXis (AVXS) and Clovis Oncology (CLVS).
How do I buy Receptos stock?
Shares of Receptos can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Receptos?
Receptos' mailing address is 3033 Science Park Road, Suite 300, SAN DIEGO, CA 92121, United States. The biopharmaceutical company can be reached via phone at +1-858-6525700.
MarketBeat Community Rating for Receptos (NASDAQ RCPT)MarketBeat's community ratings are surveys of what our community members think about Receptos and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Receptos (NASDAQ:RCPT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Receptos (NASDAQ:RCPT)
Analysts' Ratings History for Receptos (NASDAQ:RCPT)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History and Estimates Chart for Receptos (NASDAQ:RCPT)
Earnings History by Quarter for Receptos (NASDAQ RCPT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/4/2014||Q314||($0.96)||($1.19)||$1.00 million||$3.45 million||View||N/A|
|8/12/2014||Q214||($0.85)||($1.04)||$1.28 million||$1.10 million||View||N/A|
|5/12/2014||Q114||($0.84)||($1.01)||$0.49 million||$1.40 million||View||N/A|
|3/5/2014||($0.86)||($0.86)||$1.16 million||$0.77 million||View||N/A|
Earnings Estimates for Receptos (NASDAQ:RCPT)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Receptos (NASDAQ:RCPT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Receptos (NASDAQ RCPT)
Insider Trades by Quarter for Receptos (NASDAQ RCPT)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/16/2015||S. Edward Torres||Director||Sell||220,000||$178.99||$39,377,800.00|| |
|2/23/2015||S. Edward Torres||Director||Sell||47,906||$128.20||$6,141,549.20|| |
|11/11/2014||Faheem Hasnain||CEO||Sell||200,000||$109.47||$21,894,000.00|| |
|11/11/2014||Sheila Gujrathi||Insider||Sell||30,000||$108.99||$3,269,700.00|| |
|11/10/2014||Chrysa Mineo||SVP||Sell||30,000||$109.73||$3,291,900.00|| |
|11/10/2014||Faheem Hasnain||CEO||Sell||136,795||$109.69||$15,005,043.55|| |
|11/10/2014||Marcus F Boehm||CTO||Sell||40,454||$109.91||$4,446,299.14|| |
|9/23/2014||S. Edward Torres||Director||Sell||100,000||$61.36||$6,136,000.00|| |
|9/22/2014||S. Edward Torres||Director||Sell||14,318||$63.08||$903,179.44|| |
|9/22/2014||Sheila Gujrathi||Insider||Sell||30,000||$61.45||$1,843,500.00|| |
|9/19/2014||S. Edward Torres||Director||Sell||169,570||$62.55||$10,606,603.50|| |
|9/18/2014||S. Edward Torres||Director||Sell||91,513||$62.77||$5,744,271.01|| |
|9/17/2014||David A Hinkle||CAO||Sell||2,000||$64.82||$129,640.00|| |
|9/17/2014||S. Edward Torres||Director||Sell||38,917||$63.67||$2,477,845.39|| |
|9/16/2014||Graham K Cooper||CFO||Sell||50,000||$61.30||$3,065,000.00|| |
|9/2/2014||David A Hinkle||CAO||Sell||2,000||$52.80||$105,600.00|| |
|8/13/2014||David A Hinkle||CAO||Sell||3,000||$42.69||$128,070.00|| |
|8/13/2014||S. Edward Torres||Director||Sell||200,000||$43.24||$8,648,000.00|| |
|5/29/2014||Kristina Burow||Director||Sell||153,698||$29.74||$4,570,978.52|| |
|5/21/2014||S. Edward Torres||Director||Sell||424,068||$25.26||$10,711,957.68|| |
|5/15/2014||S. Edward Torres||Director||Sell||90,075||$27.37||$2,465,352.75|| |
|5/14/2014||Kristina Burow||Director||Sell||45,381||$29.66||$1,346,000.46|| |
|1/3/2014||William Rastetter||Director||Sell||37,359||$30.85||$1,152,525.15|| |
|1/2/2014||William Rastetter||Director||Sell||27,581||$30.29||$835,428.49|| |
|12/6/2013||Amir Nashat||Director||Sell||170,000||$26.70||$4,539,000.00|| |
|12/5/2013||William Rastetter||Director||Sell||500,000||$27.63||$13,815,000.00|| |
|11/18/2013||Ventures Fund 2007 Flagship||major shareholder||Sell||230,787||$24.75||$5,711,978.25|| |
|11/15/2013||Amir Nashat||Director||Sell||169,315||$24.96||$4,226,102.40|| |
|5/14/2013||Amir Nashat||Director||Buy||151,343||$14.00||$2,118,802.00|| |
|5/14/2013||Ventures Fund 2007 L Flagship||Major Shareholder||Buy||107,142||$14.00||$1,499,988.00|| |
Headline Trends for Receptos (NASDAQ:RCPT)
Latest Headlines for Receptos (NASDAQ RCPT)
Receptos (NASDAQ RCPT) Chart for Saturday, November, 18, 2017